| Nov 18 |
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
|
| Nov 8 |
Pliant Therapeutics GAAP EPS of -$0.95
|
| Nov 7 |
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
|
| Nov 6 |
Pliant Therapeutics to Participate in the Stifel Healthcare Conference
|
| Oct 17 |
Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024
|
| Oct 5 |
Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc
|
| Oct 1 |
Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs
|
| Sep 24 |
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
|
| Sep 11 |
Pliant Therapeutics: Good Data, But Will Need Watching
|
| Sep 10 |
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024
|
